IPO
-
-
-
-
-
-
-
TransCode Therapeutics (RNAZ) and BRAIN Biotech Partner to Develop a CRISPR-derived Technology Platform for Cancer Treatment
-
-
-
-
-
-
-
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
-
-
-
-
-
-
-
TransCode Therapeutics, Inc (RNAZ) Prices 6.25M Share IPO at $4/sh
-
118,853 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

